RE:$18M spent on R&D over 9 yrs$18 million in R&D to disrupt global markets dominated by giants with far greater budgets. It is an amazing accomplishment as we now sit just months from the goal line. Ronnie Miller is from a giant and knows excelelnce and is "thrilled". He's been updated by Natex, etc. He knows the plan. The finish line will soon be hear! CZO did it and now its time for NASDAQ!
The path, the daisy chain of events that will define this merger...
AEZS's diagnostic test clinical trial results for children
Launch of powder formulations of CZO's two active ingredients(beta glucan, avenanthramide). Sample has been shipped to Symrise of oat beta glucan.
CZO's main client has returned with a first shipment.
AEZS's diagnostic continuing roll-out for adults in Europe, etc., and relaunch for adults in US market
.
FDA and European approval for the diagnostic test for children
Licensing deal for the diagnostic test for North America
Commissioning of 5X PGX scale-up expected next month.
Commissioning of 10X scale-up to decision point for mass industrialization of PGX expected in the next seven months.
PGX-yeast beta glucan: "...this product could be offered as an immune booster before year end 2024."
PGX licensing deal.
Immune booster plant. The previous proposed 40 million dose plant had a 100 million net present value.
With the Q3 financials news release a protocol for an animal trial for the immune booster had been designed. This could strengthen belief in superiority for the immune booster.
Phase I avenanthramide clinical trial results. The first two cohorts show no adverse events.
Wound healing results with the Angiogenesis Foundation in ongoing study.
Wound healing partnership.
Fibrosis clinical trial 'go'/'no go' decision and regulatory filing
Phase IIa avenanthramide clinical trial results
"Ceapro’s team has successfully developed a unique, standardized formulation for a healthy confection which includes a high concentration of OBG with daily dosage according to approved claims in 10 developed countries...Ceapro’s team anticipates the official commercial launch of its approved natural health product in H2, 2024...
Avenanthramide pill partnership
AIM Biologicals 'go'/'no go' clinical trial decision and clinical development path as well as other potential assets.
Potential analyst coverage. AEZS is already covered by H.C. Wainwright with a C$100 million market cap target price. Given this is a merger of equals this may speak to the value of the combined company.
The S&P Biotech ETF has hit a new 52-week high today and has broken to a multi-year high after the worst biotech bear market in history. Gilles may have acquired AEZS's assets at the bottom with epic timing. The S&P Biotech ETF has surged 56% in four months as this merger has been put together. Many biotech assets have been trading below cash, such as AEZS's. As the biotech market breaks out and the merged company shows a path to long-term sustainability the new merged company could rebound very sharply with analyst support.
"The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business, which is optimally positioned to deliver value as the biopharma sector recovers from its current levels." news release
lscfa wrote: Nothing to show for it....
| R&D | |
| 584,665 | Q3 23 |
| 926,775 | Q2 23 |
| 573,687 | Q1 23 |
| 575,211 | Q4 22 |
| 314,250 | Q3 22 |
| 543,924 | Q2 22 |
| 355,281 | Q1 22 |
| 728,558 | Q4 21 |
| 1,403,186 | Q3 21 |
| 830,511 | Q2 21 |
| 816,847 | Q1 21 |
| 497,551 | Q4 20 |
| 478,993 | Q3 20 |
| 399,797 | Q2 20 |
| 505,542 | Q1 20 |
| 473,732 | Q4 19 |
| 307,477 | Q3 19 |
| 811,894 | Q2 19 |
| 800,504 | Q1 19 |
| 670,656 | Q4 18 |
| 997,143 | Q3 18 |
| 659,226 | Q2 18 |
| 338,813 | Q1 18 |
| 274,131 | Q4 17 |
| 435,039 | Q3 17 |
| 301,138 | Q2 17 |
| 596,024 | Q1 17 |
| 388,035 | Q4 16 |
| 264,505 | Q3 16 |
| (61,251) | Q2 16 |
| 327,832 | Q1 16 |
| 140,684 | Q4 15 |
| 141,788 | Q3 15 |
| 236,835 | Q2 15 |
| 105,907 | Q1 15 |
| 17,744,890 | |